Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John D McCarter

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Nature Cancer|December 27, 2023
Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancersMarc Payton, Brian Belmontes, Kelly Hanestad, et al.
Bioorganic & Medicinal Chemistry Letters|October 22, 2013
Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer's diseaseJian Jeffrey Chen, Wenyuan Qian, Kaustav Biswas, et al.
Journal of Medicinal Chemistry|May 3, 2012
Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinasesAdrian L Smith, Noel D D'Angelo, Yunxin Y Bo, et al.
Nature|November 1, 2019
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityJude Canon, Karen Rex, Anne Y Saiki, et al.
Journal of Medicinal Chemistry|December 4, 2014
Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune diseaseTimothy D Cushing, Xiaolin Hao, Youngsook Shin, et al.
Journal of Medicinal Chemistry|August 18, 2012
Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511Mark H Norman, Kristin L Andrews, Yunxin Y Bo, et al.
Journal of Medicinal Chemistry|December 11, 2019
Discovery of a Covalent Inhibitor of KRAS<sup>G12C</sup> (AMG 510) for the Treatment of Solid TumorsBrian A Lanman, Jennifer R Allen, John G Allen, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Nature Cancer|December 27, 2023
Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancersMarc Payton, Brian Belmontes, Kelly Hanestad, et al.
Bioorganic & Medicinal Chemistry Letters|October 22, 2013
Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer's diseaseJian Jeffrey Chen, Wenyuan Qian, Kaustav Biswas, et al.
Journal of Medicinal Chemistry|May 3, 2012
Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinasesAdrian L Smith, Noel D D'Angelo, Yunxin Y Bo, et al.
Nature|November 1, 2019
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityJude Canon, Karen Rex, Anne Y Saiki, et al.
Journal of Medicinal Chemistry|December 4, 2014
Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune diseaseTimothy D Cushing, Xiaolin Hao, Youngsook Shin, et al.
Journal of Medicinal Chemistry|August 18, 2012
Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511Mark H Norman, Kristin L Andrews, Yunxin Y Bo, et al.
Journal of Medicinal Chemistry|December 11, 2019
Discovery of a Covalent Inhibitor of KRAS<sup>G12C</sup> (AMG 510) for the Treatment of Solid TumorsBrian A Lanman, Jennifer R Allen, John G Allen, et al.
Pageof 3